Compare LQDA & LION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | LION |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 2020 | 2025 |
| Metric | LQDA | LION |
|---|---|---|
| Price | $47.98 | $14.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $54.38 | $15.33 |
| AVG Volume (30 Days) | ★ 3.9M | 3.8M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | $158,320,000.00 | ★ $2,631,800,000.00 |
| Revenue This Year | $357.27 | $29.25 |
| Revenue Next Year | $1.34 | $1.00 |
| P/E Ratio | $35.40 | ★ N/A |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $22.31 | $6.47 |
| 52 Week High | $93.61 | $16.70 |
| Indicator | LQDA | LION |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 72.52 |
| Support Level | $35.00 | $13.14 |
| Resistance Level | $63.46 | $14.78 |
| Average True Range (ATR) | 3.10 | 0.58 |
| MACD | 1.61 | 0.20 |
| Stochastic Oscillator | 77.29 | 95.62 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.